Abbisko Cayman unit completes first patient dosing in Phase I ABSK211
Abbisko Cayman says its unit has completed first patient dosing in its Phase I trial of ABSK211.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.